All Updates

All Updates

icon
Filter
Partnerships
PostEra partners with Pfizer to accelerate small molecule drug discovery
AI Drug Discovery
Dec 7, 2020
This week:
Partnerships
Apple discloses use of AWS GenAI chips at re:Invent 2024 conference
Generative AI Infrastructure
Today
Product updates
AWS launches Automated Reasoning checks to combat AI hallucinations
Generative AI Infrastructure
Today
Product updates
Roonyx releases enhanced BNPL platform to facilitate secure transactions
Buy Now, Pay Later
Yesterday
Product updates
AWS announces next generation of SageMaker platform at re:Invent 2024
Generative AI Infrastructure
Yesterday
Product updates
Equal1 launches quantum controller chip for cryogenic computing
Quantum Computing
Yesterday
Partnerships
Exotec partners with BlueStar to deploy Skypod warehouse automation system
Logistics Tech
Yesterday
Partnerships
Amaero enters long-term supply agreement with Perryman
Additive Manufacturing
Yesterday
Product updates
Raise3D launches six new resins for DF2 DLP solution
Additive Manufacturing
Yesterday
M&A
Anzu Partners acquires voxeljet for EUR 20 million
Additive Manufacturing
Yesterday
Funding
Soda Health raises USD 50 million in oversubscribed Series B funding to scale operations
Health Benefits Platforms
Yesterday
AI Drug Discovery

AI Drug Discovery

Dec 7, 2020

PostEra partners with Pfizer to accelerate small molecule drug discovery

Partnerships

  • California-based AI drug discovery company PostEra has announced a multi-year strategic partnership with the pharma giant Pfizer to accelerate small molecule drug discovery. 

  • PostEra will develop a generative chemistry-based platform by utilizing Pfizer’s extensive data and expertise to be deployed across in-house, preclinical drug discovery programs. 

  • PostEra will receive an undisclosed upfront payment and is also eligible for additional milestone payments. Ownership rights of any algorithms developed during the partnership will belong to PostEra. 

  • Founded in 2019, PostEra is a University of Cambridge spin-out company engaged in utilizing machine learning technology to design novel molecular structures. Its approach is based on combining chemical synthesis with molecular designing. In addition to collaborating with drug developers, it also operates a chemical database, Manifold, to offer some of its synthesis technology. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.